US20200283368A1 - New intermediates for the vitamin a synthesis - Google Patents

New intermediates for the vitamin a synthesis Download PDF

Info

Publication number
US20200283368A1
US20200283368A1 US16/645,614 US201816645614A US2020283368A1 US 20200283368 A1 US20200283368 A1 US 20200283368A1 US 201816645614 A US201816645614 A US 201816645614A US 2020283368 A1 US2020283368 A1 US 2020283368A1
Authority
US
United States
Prior art keywords
formula
compound
vitamin
synthesis
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/645,614
Inventor
Raphael Beumer
Werner Bonrath
Marc-André Mueller
Bettina WÜESTENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Assigned to DSM IP ASSETS B.V. reassignment DSM IP ASSETS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Mueller, Marc-André, BEUMER, RAPHAEL, BONRATH, WERNER, WÜESTENBERG, BETTINA
Publication of US20200283368A1 publication Critical patent/US20200283368A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/28Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/08Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00Grignard reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12Acetic acid esters
    • C07C69/14Acetic acid esters of monohydroxylic compounds
    • C07C69/145Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the present invention relates to new compounds, to their synthesis and their use in organic synthesis, especially in the synthesis of vitamin A, Vitamin A acetate, or ⁇ -carotene and derivatives thereof, e.g. canthaxanthin, astaxanthin or zeaxanthin.
  • the new compounds are useful as intermediates (building blocks) in the synthesis of vitamin A or ⁇ -carotene, preferably in the synthesis of vitamin A (or vitamin A acetate).
  • Vitamin A plays a role in a variety of functions throughout the (human) body, such as e.g. vision process, gene transcription, immune function, bone metabolism, haematopoiesis, skin and cellular health and antioxidant function.
  • the goal of the present invention was to find easily accessible compounds, which can then be used in an improved synthesis of vitamin A or its derivates, or ⁇ -carotene, preferably vitamin A (acetate).
  • an embodiment of the present invention is the compound of formula (I)
  • 6-Methyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5-octen-2-one can be converted into ⁇ -cyclogeranyllinalool (compound of formula (IV)) by standard organic chemistry methods, e.g. by Grignard reaction.
  • the present invention relates to a process to produce the compound of formula (II)
  • Step (i) can be carried out according to standard organic chemistry methods, e.g. Grignard reaction.
  • the compound of formula (IV) is acetylated. That can be done by commonly known compounds, such as for example acetic acid anhydride.
  • step (ii) is carried out in presence of an tertiary amine, preferred triethylamine. It is very common and preferred that also at least one nucleophilic catalyst is used, such as for example dimethyl aminopyridine.
  • step (ii) is carried out under an inert gas atmosphere.
  • step (ii) is usually carried out at elevated temperatures, usually above 30° C., (in the range of 30-80° C.).
  • step (iii) is carried out in an organic solvent.
  • suitable solvents are ethers, e.g. THF, toluene, methyl-THF, methyl cyclopentyl ether, tert.-butyl methyl ether, tert.-butyl ethyl ether, tert.-amyl methyl ether or mixtures thereof.
  • Most preferred solvents are are ethers, such as THF or 2-MeTHF.
  • step (iii) is carried out in the presence of a catalyst such bis(acetonitrile)-dichloropalladium or bis(benzonitrile)-dichloropalladium.
  • a catalyst such bis(acetonitrile)-dichloropalladium or bis(benzonitrile)-dichloropalladium.
  • the product is then isolated and usually purified by commonly known methods.
  • the compound of formula (I) is usually obtained in an overall yield (based on the compound of formula (II)) of more than 50%.
  • the compounds of formula (I) and (II) according to the present invention can be used in organic synthesis.
  • the new compounds are useful as intermediates (building blocks) in the synthesis of vitamin A or ⁇ -carotene or derivatives thereof, preferably vitamin A. Therefore, a further embodiment of the present invention relates to the use of compounds of formula (I) and (II) in organic synthesis. A preferred embodiment of the present invention relates to the use of compounds of formula (I) and (II) as intermediates (building blocks) in the synthesis of vitamin A or ⁇ -carotene, preferably vitamin A.
  • the reaction mixture was cooled to room temperature, transferred into a separation funnel and diluted with 15 ml of diethyl ether.
  • the organic layer was subsequently washed with semi-saturated NaHCO 3 solution (30 ml), water (30 ml) and brine (30 ml).
  • the aqueous layers were re-extracted with diethyl ether (30 ml).
  • the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • the crude product was purified by column chromatography (SiO 2 , cyclohexane/diisopropyl ether 8:2). The purified product was obtained as colorless liquid in 81% yield.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to the compound of formula (I). The invention further relates to the compound of formula (II). The invention further relates to the synthesis of these compounds as well as to their use in organic synthesis, especially in the synthesis of vitamin A or p-carotene and derivatives thereof, e.g. canthaxanthin, astaxanthin or zeaxanthin.
Figure US20200283368A1-20200910-C00001

Description

  • The present invention relates to new compounds, to their synthesis and their use in organic synthesis, especially in the synthesis of vitamin A, Vitamin A acetate, or β-carotene and derivatives thereof, e.g. canthaxanthin, astaxanthin or zeaxanthin.
  • Especially to be mentioned is that the new compounds are useful as intermediates (building blocks) in the synthesis of vitamin A or β-carotene, preferably in the synthesis of vitamin A (or vitamin A acetate).
  • Vitamin A or its derivatives such as Vitamin acetate
  • Figure US20200283368A1-20200910-C00002
  • is an important ingredient for many applications. Vitamin A plays a role in a variety of functions throughout the (human) body, such as e.g. vision process, gene transcription, immune function, bone metabolism, haematopoiesis, skin and cellular health and antioxidant function.
  • Due to the importance of vitamin A (and its derivatives) and the complexity of the synthesis thereof, there is always a need for improved processes of production.
  • The goal of the present invention was to find easily accessible compounds, which can then be used in an improved synthesis of vitamin A or its derivates, or β-carotene, preferably vitamin A (acetate).
  • The aim was achieved by the compounds and the synthesis as disclosed and described below.
  • Three new compounds, which are useful intermediates, have been found:
  • ρ-Cyclogeranylgeranyl acetate (compound of formula (I))
  • Figure US20200283368A1-20200910-C00003
  • as well as β-cyclogeranyllinalyl acetate (compound of formula (II))
  • Figure US20200283368A1-20200910-C00004
  • which is a precursor compound for the compound of formula (I).
  • Therefore, an embodiment of the present invention is the compound of formula (I)
  • Figure US20200283368A1-20200910-C00005
  • Therefore, another embodiment of the present invention is the compound of formula (II)
  • Figure US20200283368A1-20200910-C00006
  • The new synthesis uses 6-methyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5-octen-2-one (compound of formula (III))
  • Figure US20200283368A1-20200910-C00007
  • as a starting material.
  • 6-Methyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5-octen-2-one (compound of formula (III)) was synthesized according to literature-known procedures, such as e.g. the following way
  • Figure US20200283368A1-20200910-C00008
  • 6-Methyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5-octen-2-one can be converted into β-cyclogeranyllinalool (compound of formula (IV)) by standard organic chemistry methods, e.g. by Grignard reaction.
  • The reaction scheme of the production of the compounds of formula (I) and (II) is the following:
  • Figure US20200283368A1-20200910-C00009
  • Therefore, the present invention relates to a process to produce the compound of formula (II)
  • Figure US20200283368A1-20200910-C00010
  • wherein the compound of formula (IV)
  • Figure US20200283368A1-20200910-C00011
  • is reacted with a compound (acetic acid anhydride or similar) to form the compound of formula (II).
  • Step (i):
  • Step (i) can be carried out according to standard organic chemistry methods, e.g. Grignard reaction.
  • Step (ii):
  • The compound of formula (IV) is acetylated. That can be done by commonly known compounds, such as for example acetic acid anhydride.
  • The reaction of step (ii) is carried out in presence of an tertiary amine, preferred triethylamine. It is very common and preferred that also at least one nucleophilic catalyst is used, such as for example dimethyl aminopyridine.
  • Usually the reaction of step (ii) is carried out under an inert gas atmosphere.
  • The reaction of step (ii) is usually carried out at elevated temperatures, usually above 30° C., (in the range of 30-80° C.).
  • The product which is then obtained (compound of formula (II)) can be isolated and if needed further purified. The yields, which are obtained are usually above 80%.
  • Step (iii):
  • Compound of formula (I) is obtained by the reaction of the compound of formula (II). It is a rearrangement reaction. (step (iii)).
  • Figure US20200283368A1-20200910-C00012
  • Usually the reaction of step (iii) is carried out in an organic solvent. Suitable solvents are ethers, e.g. THF, toluene, methyl-THF, methyl cyclopentyl ether, tert.-butyl methyl ether, tert.-butyl ethyl ether, tert.-amyl methyl ether or mixtures thereof. Most preferred solvents are are ethers, such as THF or 2-MeTHF.
  • Usually the reaction of step (iii) is carried out in the presence of a catalyst such bis(acetonitrile)-dichloropalladium or bis(benzonitrile)-dichloropalladium.
  • The product is then isolated and usually purified by commonly known methods. The compound of formula (I) is usually obtained in an overall yield (based on the compound of formula (II)) of more than 50%.
  • The compounds of formula (I) and (II) according to the present invention can be used in organic synthesis.
  • Preferably the new compounds are useful as intermediates (building blocks) in the synthesis of vitamin A or β-carotene or derivatives thereof, preferably vitamin A. Therefore, a further embodiment of the present invention relates to the use of compounds of formula (I) and (II) in organic synthesis. A preferred embodiment of the present invention relates to the use of compounds of formula (I) and (II) as intermediates (building blocks) in the synthesis of vitamin A or β-carotene, preferably vitamin A.
  • The following examples serve to illustrate the invention. The temperature is given in ° C. and all percentages are related to the weight.
  • EXAMPLES Example 1: Synthesis of β-cyclogeranyllinalool
  • Under inert gas atmosphere, 22 mmol of (E)-6-methyl-8-(2,6,6-trimethylcyclohex-1-en-1-yl)oct-5-en-2-one (III) were dissolved in 22 ml of anhydrous THF. The solution was cooled to 0-5° C. with an ice-bath. Over 2 hours, 33 mmol vinyl magnesium bromide solution (1 M in THF) were added dropwise so that the temperature remains between 0-5° C. After complete addition, stirring was continued for 1 hour. After that the ice-bath was removed and the reaction was warmed to room temperature. After 1 hour at 24° C., sat. NH4Cl-solution (30 ml) was added dropwise over 10 min (exothermic). After stirring for another 30 min the mixture was diluted with methylene chloride (100 ml) and washed with brine (2×45 ml). The aqueous layers were re-extracted with methylene chloride (2×100 ml). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatopgraphy (SiO2, cyclohexane/diisopropyl ether 8:2).
  • Example 2: Synthesis of β-cyclogeranyllinalool Acetate
  • Under inert gas atmosphere, 3.44 mmol β-cyclogeranyllinalool were dissolved in 6.9 ml of toluene. At room temperature, 8.61 mmol of triethylamine and 1.722 mmol of dimethyl aminopyridine (DMAP) were added. To the colorless solution were added 8.61 mmol of acetic acid anhydride. Then the reaction mixture was warmed to 50° C. and stirred for 2 hours.
  • The reaction mixture was cooled to room temperature, transferred into a separation funnel and diluted with 15 ml of diethyl ether. The organic layer was subsequently washed with semi-saturated NaHCO3 solution (30 ml), water (30 ml) and brine (30 ml). The aqueous layers were re-extracted with diethyl ether (30 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (SiO2, cyclohexane/diisopropyl ether 8:2). The purified product was obtained as colorless liquid in 81% yield.
  • Example 3: Synthesis of β-cyclogeranylgeraniol Acetate
  • Under inert gas atmosphere, 0.05 mmol bis(acetonitrile)-dichloropalladium were dissolved in 1 ml of anhydrous THF. At room temperature, a solution of 1 mmol of β-cyclogeranyllinalool acetate in 4 ml of anhydrous THF was added within 20 min. After stirring for 4 hours at room temperature, the reaction was complete. The solvent was removed and the crude product was purified by column chromatography (SiO2, n-hexane/ethyl acetate 95:5). The purified product was obtained as yellow liquid in 50% yield.

Claims (8)

1. A compound of formula (I)
Figure US20200283368A1-20200910-C00013
2. A compound of formula (II)
Figure US20200283368A1-20200910-C00014
3. A process of production of the compound of formula (II)
Figure US20200283368A1-20200910-C00015
wherein the compound of formula (IV)
Figure US20200283368A1-20200910-C00016
is reacted with acetic acid anhydride or similar to form the compound of formula (II).
4. A process of production of the compound of formula (I),
Figure US20200283368A1-20200910-C00017
wherein the compound of formula (II)
Figure US20200283368A1-20200910-C00018
is catalytically rearranged.
5. Use of the compound of formula (I) in organic synthesis.
6. Use according to claim 5, wherein the vitamin A or β-carotene are produced (preferably vitamin A).
7. Use of the compound of formula (II) in organic synthesis.
8. Use according to claim 7, wherein the vitamin A or β-carotene are produced (preferably vitamin A).
US16/645,614 2017-09-22 2018-09-13 New intermediates for the vitamin a synthesis Abandoned US20200283368A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192631.4 2017-09-22
EP17192631 2017-09-22
PCT/EP2018/074748 WO2019057600A1 (en) 2017-09-22 2018-09-13 New intermediates for the vitamin a synthesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/074748 A-371-Of-International WO2019057600A1 (en) 2017-09-22 2018-09-13 New intermediates for the vitamin a synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/676,077 Continuation US11851404B2 (en) 2017-09-22 2022-02-18 Intermediates for the vitamin A synthesis

Publications (1)

Publication Number Publication Date
US20200283368A1 true US20200283368A1 (en) 2020-09-10

Family

ID=60019682

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/645,614 Abandoned US20200283368A1 (en) 2017-09-22 2018-09-13 New intermediates for the vitamin a synthesis
US17/676,077 Active US11851404B2 (en) 2017-09-22 2022-02-18 Intermediates for the vitamin A synthesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/676,077 Active US11851404B2 (en) 2017-09-22 2022-02-18 Intermediates for the vitamin A synthesis

Country Status (4)

Country Link
US (2) US20200283368A1 (en)
EP (2) EP3684748A1 (en)
CN (1) CN111108086A (en)
WO (1) WO2019057600A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021130059A1 (en) * 2019-12-23 2021-07-01 Dsm Ip Assets B.V. Functionalisation of 1,3-alpha-dienes (ii)
US20230192605A1 (en) * 2020-03-31 2023-06-22 Dsm Ip Assets B.V. Process for production of intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062875A (en) 1962-11-06 Displacement reactions of myrcene
CH168135A (en) * 1933-03-03 1934-03-31 Chem Ind Basel Process for the preparation of an unsaturated monocyclic primary diterpene alcohol of the type of vitamin A.
US2369166A (en) * 1942-03-03 1945-02-13 Research Corp Synthesis of vitamin a
US2451739A (en) 1945-10-18 1948-10-19 Hoffmann La Roche Process for the manufacture of pentaenes
US3928400A (en) 1972-11-02 1975-12-23 Hoffmann La Roche Process for producing vitamin A

Also Published As

Publication number Publication date
WO2019057600A1 (en) 2019-03-28
EP3684748A1 (en) 2020-07-29
EP4324819A2 (en) 2024-02-21
US20220169590A1 (en) 2022-06-02
CN111108086A (en) 2020-05-05
US11851404B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
US11851404B2 (en) Intermediates for the vitamin A synthesis
US10106477B2 (en) Process for preparing 1,4-bis(ethoxymethyl)cyclohexane
US10494322B2 (en) Method for producing 3,7-dimethyl-7-octenol and method for producing 3,7-dimethyl-7-octenyl carboxylate compound
US9040742B2 (en) Catalytic synthesis of vitamin A intermediate
US9309194B2 (en) Intermediates for the vitamin A and β-carotene synthesis
US20110137041A1 (en) Process for preparing atovaquone and associate intermediates
US9067877B2 (en) Process for the production of 1,3,3-trimethyl-2-(3-methylpent-2-en-4-ynyl)cyclohex-1-ene
EP3655385B1 (en) Process of production of 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-nona-2e,7e-dien-4-yne-1,6-diol
US20060224016A1 (en) Process for preparing 3-aminophenylacetylenes
EP2066624B1 (en) Improved method of production of 9-cis-retinoic acid
EP1615879A1 (en) Process for the production of 9-cis retinoic acid
WO2019016315A1 (en) Process of production of 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-nona-2z,7e-dien-4-yne-1,6-diol
US20230192605A1 (en) Process for production of intermediates
US20240116843A1 (en) Process for the preparation of vitamin k2 and novel intermediates
CN116724030A (en) Method for producing an intermediate
CN111484510A (en) Preparation method of (2,6, 6-trimethyl-1-cyclohexenyl) aldehyde
CN117693501A (en) Process for preparing gossypin
KR100570279B1 (en) Intermediates of coenzyme qn and process for the preparation thereof
JPH0567630B2 (en)
JPH0822846B2 (en) Method for producing cyclic terpene compound
KR20040086915A (en) Processes For Preparing Allylic alcohol Derivatives
JP2012087078A (en) Method for producing alkylsulfinyl chloride
JPS63227565A (en) Production of allylsulfone
JPH07109244A (en) Production of 5-bromo-2-pentanone

Legal Events

Date Code Title Description
AS Assignment

Owner name: DSM IP ASSETS B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEUMER, RAPHAEL;BONRATH, WERNER;MUELLER, MARC-ANDRE;AND OTHERS;SIGNING DATES FROM 20200121 TO 20200131;REEL/FRAME:052053/0285

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION